CTAD 2017

Boston, MA – USA – November 2-4

The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.

Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.

The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2016 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD. Again in 2017 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.

CTAD 2017 will highlight the latest on trying to get these trials off the ground.

Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.

We look forward to seeing you in Boston!

For more information please visit our website www.ctad-alzheimer.com or contact the CTAD 2017 secretariat at ctad@ant-congres.com

CTAD 2017 Scientific Committee

Susan ABUSHAKRA (San Francisco) Paul AISEN (San Diego) Kaj BLENNOW (Molndal) Merce BOADA (Barcelona) Robert BRASHEAR (San Francisco) Maria CARRILLO (Chicago) Mony John DE LEON (New York) Rachelle DOODY (Houston) Bruno DUBOIS (Paris) Howard FELDMAN (Vancouver) Nick FOX (London) Giovanni B. FRISONI (Brescia) Lutz FROELICH (Mannheim) Serge GAUTHIER (Montreal) Ezio GIACOBINI (Geneva) Michael GRUNDMANN (San Diego) Harald HAMPEL (Munich) Takeshi IWATSUBO (Tokyo) Ara KHACHATURIAN (Washington DC) Zaven KHACHATURIAN (Washington DC)

Virginia LEE (Philadelphia) José Luis MOLINUEVO (Barcelona) Jean-Marc ORGOGOZO (Bordeaux) Ronald PETERSEN (Minnesota) Craig W. RITCHIE (Edinburgh) Augustin Ruiz (Barcelona) Stephen SALLOWAY (Providence) Philip SCHELTENS (Amsterdam)  Lon SCHNEIDER (Los Angeles) Eric SIEMERS (Philadelphia) Peter SNYDER (Rhode Island) Reisa SPERLING (Boston) Yaakov STERN (New York) Jacques TOUCHON (Montpellier) John TROJANOWSKI (Philadelphia) Bruno VELLAS (Toulouse) Michael W. WEINER (San Francisco) Gordon WILCOCK (Oxford) Bengt WINBLAD (Stockholm)